SUCRALFATE

Post-LOE

sucralfate oral

Partner Therapeutics

ANDAORALSUSPENSION

Approved

Jan 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Mechanism of Action

Pharmacologic Class:

Aluminum Complex

Company

Partner Therapeutics

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers